Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study

Adam J Olszewski, MD, Matthew S. Davids, MD, Inna Yakirevich, NP, Pamela C Egan, MD

Blood (2019) 134 (Supplement_1): 265.

https://doi.org/10.1182/blood-2019-122516

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy

Chloe Pek Sang Tang, MBBS, FRACP, Andre La Gerche, Julie McMullen, BSc(Hons) PhDFCSANZ FAHA, Erin Howden, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Isaac Goncalves, MBBS PhDFRACP, Jenny Ooi, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4301.

https://doi.org/10.1182/blood-2019-129808

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Tyler Dickerson, PharmD, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Devin Haddad, Avirup Guha, Kyle Porter, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, John C. Byrd, MD, Daniel Addison, Farrukh T. Awan, MD MS

Blood (2018) 132 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2018-99-110345

Published: 2018

Journal Articles

Incidence, Clinical Characteristics and Outcome of Cardiac Toxicity in Elderly Patients with Diffuse Large B-Cell Lymphoma

Wei Ping Liu, Yan Feng Xu, Yan Xie, Xiaopei Wang, MD, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5416.

https://doi.org/10.1182/blood-2018-99-117955

Published: 2018

Journal Articles

The Widow Maker: A National Inpatient Sample Study of Health Care Utilization Costs for Cardiovascular Complications Patients Diagnosed with Non-Hodgkin's Lymphoma from 2000-2014

Ragisha Gopalakrishnan, MD, Shruti Chaturvedi, MBBS,MS

Blood (2017) 130 (Supplement 1): 4696.

https://doi.org/10.1182/blood.V130.Suppl_1.4696.4696

Published: 2017

Journal Articles

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 2767.

https://doi.org/10.1182/blood.V130.Suppl_1.2767.2767

Published: 2017

Journal Articles

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Benjamin L. Lampson, Lijian Yu, Robert J. Glynn, Jacqueline C. Barrientos, Eric D. Jacobsen, Versha Banerji, Jeffrey A. Jones, Renata Walewska, Kerry J. Savage, Gregory F. Michaud, Javid J. Moslehi, Jennifer R. Brown

Blood (2017) 129 (18): 2581–2584.

https://doi.org/10.1182/blood-2016-10-742437

Published: 2017

Includes: Supplemental data

Journal Articles

Cardiovascular Comorbidities in a United States Patient Population with Hemophilia a: A Comprehensive Chart Review

Jennifer Pocoski, Brittny Rule, Augustina Ogbonnaya, MPH, Lois Lamerato, PhD, Michael Eaddy, PharmD, PhD, Orsolya Lunacsek, Thomas J. Humphries

Blood (2016) 128 (22): 4966.

https://doi.org/10.1182/blood.V128.22.4966.4966

Published: 2016

Journal Articles

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Kieron Dunleavy, MD, Catherine E. Lai, MD, Mark Roschewski, MD, Jennifer N Brudno, MD, Brigitte Widemann, MD, Stefania Pittaluga, MD PhD, Elaine S Jaffe, MD, Andrea N Lucas, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Pamela Harris, MD, Diane Cole, John A Butman, MD, Richard F Little, MD, Louis M Staudt, MD, Wyndham H Wilson, MD PhD

Blood (2015) 126 (23): 472.

https://doi.org/10.1182/blood.V126.23.472.472

Published: 2015

Journal Articles

A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study

Robert B Kleiman, Rajesh Chopra, de Haan Hans, Kristen Hege, Angela J James, Xiaomin Wang, Xiaoling Wu, Edward O'Mara

Blood (2015) 126 (23): 5555.

https://doi.org/10.1182/blood.V126.23.5555.5555

Published: 2015

Journal Articles

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Jeffrey Zonder, MD, Christiane Houde, BS, Sascha Tuchman, MD, Vishal Kukreti, MD, Vaishali Sanchorawala, MD, Silva Pregja, MBA, Kathy A Reichel, Steven M Burt, NP, Colleen Neveux, RN, Jeffrey Matous, MD

Blood (2014) 124 (21): 4767.

https://doi.org/10.1182/blood.V124.21.4767.4767

Published: 2014

Journal Articles

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Blood (2014) 124 (21): 796.

https://doi.org/10.1182/blood.V124.21.796.796

Published: 2014

Journal Articles

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Harry J Iland, MBBS FRACP FRCPA, Marnie Collins, BCom BSc(Hons), Mark S Hertzberg, MBBS PhDFRACP FRCPA, Michael Seldon, MBBS FRACP FRCPA, Andrew P Grigg, MBBS FRACP FRCPA MD, Frank Firkin, MBBS PhDFRACP FRCPA, Shane G Supple, BSc(Hons) PhD, Lynda J Campbell, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 375.

https://doi.org/10.1182/blood.V124.21.375.375

Published: 2014

Journal Articles

Mechanistic Insights Into Ventricular Arrhythmias Associated With Sickle Cell Disease: Role Of Abnormal Repolarization

I D Greener, Ph.D., C A Rutledge, BS, T Abassi, BS, K Yadav, BS, A B Desai, MD, M Oberoi, MD, P Chunduru, MD, D P Parikh, MD, J GN Garcia, MD, Victor R. Gordeuk, MD, Cheryl A. Hillery, MD, S c Dudley, Jr., MD, Roberto F Machado, MD, A A Desai, MD

Blood (2013) 122 (21): 980.

https://doi.org/10.1182/blood.V122.21.980.980

Published: 2013

Journal Articles

High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors

Giovanni Palladini, MD, Paolo Milani, MD, Marta Vidus Rosin, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2013) 122 (21): 288.

https://doi.org/10.1182/blood.V122.21.288.288

Published: 2013

Journal Articles

Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Marika Masselli, Serena Pillozzi, Massimo D'Amico, Luca Gasparoli, Olivia Crociani, Matteo Stefanini, Kennet Mugridge, Wolfang Tiedke, Andrea Becchetti, Annarosa Arcangeli, MD, PhD

Blood (2012) 120 (21): 1506.

https://doi.org/10.1182/blood.V120.21.1506.1506

Published: 2012

NARROW

Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Incidence, Clinical Characteristics and Outcome of Cardiac Toxicity in Elderly Patients with Diffuse Large B-Cell Lymphoma

The Widow Maker: A National Inpatient Sample Study of Health Care Utilization Costs for Cardiovascular Complications Patients Diagnosed with Non-Hodgkin's Lymphoma from 2000-2014

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Cardiovascular Comorbidities in a United States Patient Population with Hemophilia a: A Comprehensive Chart Review

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Mechanistic Insights Into Ventricular Arrhythmias Associated With Sickle Cell Disease: Role Of Abnormal Repolarization

High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors

Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only